STOCK DIVIDEND ISSUE PRICE
Date: 30 May 2025
Release: Before opening of Euronext
Please open the following link to read the full report including annexes:AttachmentFULL PRESS RELEASE
Day: May 30, 2025
EssilorLuxottica to acquire Optegra clinics, another leap forward in its med-tech strategy
Written by Customer Service on . Posted in Mergers And Acquisitions.
EssilorLuxottica to acquire Optegra clinics,another leap forward in its med-tech strategy
Acquisition of leading ophthalmology platform from MidEuropa will advance the Group’s development of the most comprehensive and digital-forward patient journey
Paris, France and London, United Kingdom (30 May 2025) – EssilorLuxottica and MidEuropa announced today they entered into an agreement for EssilorLuxottica to acquire Optegra, a fast-growing and highly integrated ophthalmology platform operating in five key European markets: the UK, Czech Republic, Poland, Slovakia and the Netherlands.
The acquisition represents a significant milestone in EssilorLuxottica’s med-tech strategy, building on the Group’s offering which today spans far beyond frames and lenses to include AI-powered innovative technologies, wearables, medical instruments and science-backed...
ZETADISPLAY AB (publ) INTERIM REPORT 1 JANUARY – 31 MARCH 2025
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
Q1 Interim report JANUARY – MARCH 2025 for ZetaDisplay AB (publ) is now available at ir.zetadisplay.com
Report summary:
Continued Growth and Strategic Wins Position ZetaDisplay for the Future
JANUARY – MARCH 2025Adjusted recurring revenue* increased by 9.9% to 65.4 (59.5) million
Recurring revenue increased by 7.4% to 65.4 (60.9) million
Adjusted net sales* increased by 26.8% to SEK 159.6 (125.9) million
Net sales increased by 25.5% to SEK 159.6 (127.2) million
Gross margin decreased to 56.4% (59.9 %)
Adjusted gross margin* decreased to 56.4% (59.5%)
Adjusted EBITDA* increased to SEK 22.0 (11.5) million * Recurring revenue for the first quarter of 2024 has been reduced by SEK 1.3 million to reflect the restructuring of our German operations, during which certain non-core activities were identified for discontinuation.CEO...
Unaudited consolidated financial results of VILVI Group for 3 months of 2025
Written by Customer Service on . Posted in Public Companies.
Preliminary unaudited data, consolidated sales revenue of VILVI Group for 3 months of 2025 amounted to EUR 71.1 million – 26.5% increased comparing to the same period last year (consolidated revenue of 3 months of 2024 amounted to EUR 56.2 million).
The Group earned EUR 4.0 million consolidated net profit over the first three months of 2025 or 17.8% less than in the same period 2024 (net profit for Q1 2024 was EUR 4.9 million).
The Group consists of Vilkyškių pieninė, Modest, Kelmės pieninė, Kelmės pienas, Pieno logistika (Lithuania) and Baltic Dairy Board (Latvia).Vilvi Group’s consolidated sales revenue of 2024 amounted to EUR 245.4 million. Group’s net profit for 2024 was EUR 25.7million, EBITDA amounted to EUR 33.6 million.
Please find attached presentation of consolidated unaudited results of VILVI Group for 3 months of 2025.
Vilija...
Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials
Written by Customer Service on . Posted in Public Companies.
AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically meaningful benefit
AERIFY-2, a second Phase 3 trial, did not meet the primary endpoint despite a benefit seen earlier in the trial
Itepekimab was generally well tolerated in both AERIFY-1 and AERIFY-2, with safety consistent with prior clinical trials
Regeneron and Sanofi are assessing the data and will discuss next steps with regulatory authorities
TARRYTOWN, N.Y. and PARIS, May 30, 2025 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a Phase 3 trial, AERIFY-1, evaluating the investigational use of itepekimab in adults who were former smokers with inadequately controlled chronic obstructive...
Roche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing multiple sclerosis
Written by Customer Service on . Posted in Public Companies.
Patients on fenebrutinib had low relapse rates with data showing no active brain lesions or disability progression after nearly two years of treatment
Phase III studies for fenebrutinib in relapsing and primary progressive multiple sclerosis are expected to start reading out at year endBasel, 30 May 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new, 96-week data for fenebrutinib demonstrating that patients with relapsing multiple sclerosis (RMS) maintained no disability progression and low levels of disease activity for up to two years. The latest results for this investigational Bruton’s tyrosine kinase (BTK) inhibitor from the Phase II FENopta open-label extension (OLE) study were presented at the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting in Phoenix, Arizona.
“These data show that patients treated...
RomReal: First Quarter (Q1) 2025 Results and Investor Presentation
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
RomReal hereby announces the results of the first quarter of 2025 via the report and investor presentation attached to this message.
A webcast presentation will also be uploaded on our website www.romreal.com on 30 May 2025.
For further information please contact:
Investor Relations
RomReal
investors@romreal.com
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading ActAttachmentsRomReal Q1 2025 ReportRomReal Q1 2025 Presentation
High Arctic Overseas Announces 2025 First Quarter Results
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW
CALGARY, Alberta, May 30, 2025 (GLOBE NEWSWIRE) — High Arctic Overseas Holdings Corp. (TSXV: HOH) (“High Arctic Overseas” or the “Corporation”) has released its first quarter 2025 financial and operating results. The unaudited condensed interim consolidated financial statements (the “Financial Statements”) and management’s discussion & analysis (“MD&A”) for the quarter ended March 31, 2025, will be available on SEDAR+ at www.sedarplus.ca. All amounts are denominated in United States dollars (“USD”), unless otherwise indicated.
The common shares of the Corporation began trading on the TSXV on August 16, 2024 under...
Quantum eMotion Announces Brokered LIFE Financing of C$6,000,000
Written by Customer Service on . Posted in Public Companies.
NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
MONTREAL, May 29, 2025 (GLOBE NEWSWIRE) — Quantum eMotion Corp. (“QeM” or the “Corporation”) (TSX.V: QNC; OTCQB: QNCCF) is pleased to announce a best efforts brokered private placement for total gross proceeds of at least C$6,000,000 (the “Offering”), consisting of at least 4,000,000 units of the Corporation (each a “Unit”) at a price of C$1.50 per Unit (the “Offering Price”), pursuant to the listed issuer financing exemption (the “LIFE Exemption”) under Part 5A of National Instrument 45-106 – Prospectus Exemptions (“NI 45-106”).
Each Unit will consist of (i) one common share in the capital of the Corporation (a “Share”), and (ii) one common share purchase warrant (a “Warrant”). Each Warrant will entitle the holder to acquire one additional...
